“As we invest to scale production of our commercial biomaterial products to meet expected demand in the United States and the Middle East, we are prioritizing our most promising cell therapy product candidates and programs and are rebalancing our workforce and identifying targeted expense reductions to support these priorities,” said CEO Robert J. Hariri.
If you are not happy with the results below please do another search
50 search results for:
“2023’s NYF Health Executive Jury are recognized for their exceptional reputation and world-renowned award-winning work,” said Scott Rose, President, New York Festivals Advertising Awards Competitions.
The company is testing Carvykti in multiple myeloma patients, with a history of relapse, who have stopped responding to existing treatment and have received one to three prior therapies.
The FDA approved Merck’s Keytruda for the treatment of stage IB, II or IIIA non-small cell lung cancer after resection or platinum-based chemotherapy.
The companies announced today that the EU approval is indicated for treating children as young as 6 months old with severe atopic dermatitis.
As the industry leader in delivering complementary, integrated and specialized capabilities across the commercialization continuum, Fulling will be accountable for the overall strategy, organizational leadership, financial performance, and next-level growth of this market-leading commercial enterprise.
The application to the EMA was based on results from a late-stage study that showed the drug slowed down the rate of cognitive decline in patients with early Alzheimer’s by 27%, compared with a placebo.
The treatment is not expected to neutralize the currently dominant XBB.1.5 subvariant of Omicron.
Cannabis products, excluding Jazz Pharmaceuticals Plc’s epilepsy drug Epidiolex, are illegal at the federal level in the United States, although some states allow their use.
As the healthcare journey for patients living with cancer has changed, so has the way in which pharmaceutical companies bring a drug to market. Med Ad News spoke with Anne Marie Robertson, SVP, strategy & marketing, EVERSANA about how companies need to rethink traditional commercialization models in oncology to be agile in today’s market.